|
1
|
Gosu V, Basith S, Kwon OP and Choi S:
Therapeutic applications of nucleic acids and their analogues in
Toll-like receptor signaling. Molecules. 17:13503–13529. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Takagi M: Toll-like receptor - a potent
driving force behind rheumatoid arthritis. J Clin Exp Hematop.
51:77–92. 2011.PubMed/NCBI
|
|
3
|
Chang YJ, Wu MS, Lin JT and Chen CC:
Helicobacter pylori-Induced invasion and angiogenesis of
gastric cells is mediated by cyclooxygenase-2 induction through
TLR2/TLR9 and promoter regulation. J Immunol. 175:8242–8252. 2005.
View Article : Google Scholar
|
|
4
|
Eiró N1, Altadill A, Juárez LM, et al:
Toll-like receptors 3, 4 and 9 in hepatocellular carcinoma:
Relationship with clinicopathological characteristics and
prognosis. Hepatol Res. Jun 6–2013.(Epub ahead of print).
|
|
5
|
Zhang L, Qin H, Guan X, Zhang K and Liu Z:
The TLR9 gene polymorphisms and the risk of cancer: evidence from a
meta-analysis. PLoS One. 8:e717852013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sorrentino R, Morello S, Giordano MG, et
al: CpG-ODN increases the release of VEGF in a mouse model of lung
carcinoma. Int J Cancer. 128:2815–2822. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Droemann D, Albrecht D, Gerdes J, et al:
Human lung cancer cells express functionally active Toll-like
receptor 9. Respir Res. 6:12005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Belmont L, Rabbe N, Antoine M, et al:
Expression of TLR9 in tumor-infiltrating mononuclear cells enhances
angiogenesis and is associated with a worse survival in lung
cancer. Int J Cancer. 134:765–777. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ren T, Wen ZK, Liu ZM, Liang YJ, Guo ZL
and Xu L: Functional expression of TLR9 is associated to the
metastatic potential of human lung cancer cell: functional active
role of TLR9 on tumor metastasis. Cancer Biol Ther. 6:1704–1709.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bartel DP: MicroRNAs: genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lee RC, Feinbaum RL and Ambros V: The
C. elegans heterochronic gene lin-4 encodes small RNAs with
antisense complementarity to lin-14. Cell. 75:843–854. 1993.
|
|
12
|
Cuellar TL and McManus MT: MicroRNAs and
endocrine biology. J Endocrinol. 187:327–332. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Krol J, Loedige I and Filipowicz W: The
widespread regulation of microRNA biogenesis, function and decay.
Nat Rev Genet. 11:597–610. 2010.PubMed/NCBI
|
|
14
|
Miller AM, Gilchrist DS, Nijjar J, et al:
MiR-155 has a protective role in the development of non-alcoholic
hepatosteatosis in mice. PLoS One. 8:e723242013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ma Y, Bao-Han W, Lv X, et al: MicroRNA-34a
mediates the autocrine signaling of PAR2-activating proteinase and
its role in colonic cancer cell proliferation. PLoS One.
8:e723832013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yang X, Du WW, Li H, et al: Both mature
miR-17-5p and passenger strand miR-17-3p target TIMP3 and induce
prostate tumor growth and invasion. Nucleic Acids Res.
41:9688–9704. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Qian X, Zhao P, Li W, et al: MicroRNA-26a
promotes tumor growth and angiogenesis in glioma by directly
targeting prohibitin. CNS Neurosci Ther. 19:804–812.
2013.PubMed/NCBI
|
|
18
|
Zhang J, Han C and Wu T: MicroRNA-26a
promotes cholangiocarcinoma growth by activating β-catenin.
Gastroenterology. 143:246–256. e2482012.PubMed/NCBI
|
|
19
|
Savry A, Carre M, Berges R, et al:
Bcl-2-enhanced efficacy of microtubule-targeting chemotherapy
through Bim overexpression: implications for cancer treatment.
Neoplasia. 15:49–60. 2013.
|
|
20
|
Bhattacharya D and Yusuf N: Expression of
Toll-like receptors on breast tumors: taking a toll on tumor
microenvironment. Int J Breast Cancer. 2012:7165642012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
He W, Liu Q, Wang L, Chen W, Li N and Cao
X: TLR4 signaling promotes immune escape of human lung cancer cells
by inducing immunosuppressive cytokines and apoptosis resistance.
Mol Immunol. 44:2850–2859. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Min R, Zun Z, Siyi L, et al: Increased
expression of Toll-like receptor-9 has close relation with tumour
cell proliferation in oral squamous cell carcinoma. Arch Oral Biol.
56:877–884. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Esquela-Kerscher A and Slack FJ: Oncomirs
- microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006.
View Article : Google Scholar
|
|
24
|
Majumder S and Jacob ST: Emerging role of
microRNAs in drug-resistant breast cancer. Gene Expr. 15:141–151.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Minguez B and Lachenmayer A: Diagnostic
and prognostic molecular markers in hepatocellular carcinoma. Dis
Markers. 31:181–190. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen R, Alvero AB, Silasi DA, et al:
Regulation of IKKbeta by miR-199a affects NF-kappaB activity in
ovarian cancer cells. Oncogene. 27:4712–4723. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wendlandt EB, Graff JW, Gioannini TL,
McCaffrey AP and Wilson ME: The role of microRNAs miR-200b and
miR-200c in TLR4 signaling and NF-κB activation. Innate Immun.
18:846–855. 2012.PubMed/NCBI
|
|
28
|
Chen R, Alvero AB, Silasi DA, Steffensen
KD and Mor G: Cancers take their Toll - the function and regulation
of Toll-like receptors in cancer cells. Oncogene. 27:225–233. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Xu L, Zhou Y, Liu Q, et al: CXCR4/SDF-1
pathway is crucial for TLR9 agonist enhanced metastasis of human
lung cancer cell. Biochem Biophys Res Commun. 382:571–576. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tserel L, Runnel T, Kisand K, et al:
MicroRNA expression profiles of human blood monocyte-derived
dendritic cells and macrophages reveal miR-511 as putative positive
regulator of Toll-like receptor 4. J Biol Chem. 286:26487–26495.
2011. View Article : Google Scholar
|
|
31
|
Chen X and Zhou JY, Zhao J, Chen JJ, Ma SN
and Zhou JY: Crizotinib overcomes hepatocyte growth factor-mediated
resistance to gefitinib in EGFR-mutant non-small-cell lung cancer
cells. Anticancer Drugs. 24:1039–1046. 2013. View Article : Google Scholar : PubMed/NCBI
|
